Associations - MK-2206

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MK-2206 Sensitive: C2 – Inclusion Criteria MK-2206 Sensitive : C2	MK-2206 Sensitive: C2 – Inclusion Criteria MK-2206 Sensitive : C2
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4
PTEN mutation	Pancreatic Cancer	PTEN mutation	Pancreatic Cancer	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4
MLL rearrangement	Childhood B Acute Lymphoblastic Leukemia	MLL rearrangement	Childhood B Acute Lymphoblastic Leukemia	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
FGFR2 N549K	Endometrial Cancer	FGFR2 N549K	Endometrial Cancer	futibatinib + MK-2206 Sensitive: D – Preclinical futibatinib + MK-2206 Sensitive : D	futibatinib + MK-2206 Sensitive: D – Preclinical futibatinib + MK-2206 Sensitive : D
HRAS G13R	Thyroid Gland Anaplastic Carcinoma	HRAS G13R	Thyroid Gland Anaplastic Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA mutation	Thyroid Gland Carcinoma	PIK3CA mutation	Thyroid Gland Carcinoma	temsirolimus + MK-2206 Sensitive: D – Preclinical temsirolimus + MK-2206 Sensitive : D	temsirolimus + MK-2206 Sensitive: D – Preclinical temsirolimus + MK-2206 Sensitive : D
PTEN deletion	Lung Adenocarcinoma	PTEN deletion	Lung Adenocarcinoma	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D	selumetinib + MK-2206 Sensitive: D – Preclinical selumetinib + MK-2206 Sensitive : D
PTEN R130del	Thyroid Gland Papillary Carcinoma	PTEN R130del	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	vemurafenib + MK-2206 Sensitive: D – Preclinical vemurafenib + MK-2206 Sensitive : D	vemurafenib + MK-2206 Sensitive: D – Preclinical vemurafenib + MK-2206 Sensitive : D
PIK3CA E545K	Breast Cancer	PIK3CA E545K	Breast Cancer	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	MK-2206 + D9 Sensitive: D – Preclinical MK-2206 + D9 Sensitive : D	MK-2206 + D9 Sensitive: D – Preclinical MK-2206 + D9 Sensitive : D
PTEN deletion	Melanoma	PTEN deletion	Melanoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
NRAS Q61R	Thyroid Gland Anaplastic Carcinoma	NRAS Q61R	Thyroid Gland Anaplastic Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	RET-PTC1 rearrangement	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA mutation	Thyroid Gland Carcinoma	PIK3CA mutation	Thyroid Gland Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA E545K	Thyroid Gland Papillary Carcinoma	PIK3CA E545K	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
PIK3CA H1047R	Thyroid Gland Anaplastic Carcinoma	PIK3CA H1047R	Thyroid Gland Anaplastic Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
RET rearrangement	Thyroid Gland Papillary Carcinoma	RET rearrangement	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	dasatinib + MK-2206 Sensitive: D – Preclinical dasatinib + MK-2206 Sensitive : D	dasatinib + MK-2206 Sensitive: D – Preclinical dasatinib + MK-2206 Sensitive : D
AKT1 Q79K	Melanoma	AKT1 Q79K	Melanoma	vemurafenib + MK-2206 Sensitive: D – Preclinical vemurafenib + MK-2206 Sensitive : D	vemurafenib + MK-2206 Sensitive: D – Preclinical vemurafenib + MK-2206 Sensitive : D
FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
EGFRVIII overexpression	Glioblastoma	EGFRVIII overexpression	Glioblastoma	enzalutamide + MK-2206 Sensitive: D – Preclinical enzalutamide + MK-2206 Sensitive : D	enzalutamide + MK-2206 Sensitive: D – Preclinical enzalutamide + MK-2206 Sensitive : D

MK-2206

Associations
(27)

Associations
(27)

MK-2206

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)